Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06248450
Other study ID # 2023-04481-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2023
Est. completion date December 2024

Study information

Verified date February 2024
Source Linkoeping University
Contact Anna Strömberg, PHD
Phone +46-73-6569265
Email anna.stromberg@liu.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To enhance the implementation of yoga in cancer care, studies that explore patients with cancer preferences for the execution of yoga, effects, and the experience of participating in group yoga sessions online compared to in-person sessions is required. The aim of the YouCanPrefer-study is to explore preferences, expectations, implementation, experiences, and effects of participating in in-person group yoga sessions at a yoga studio compared to participating in online-yoga at home for patients with cancer undergoing oncological treatment. Additionally, the aim is to study health-related outcomes of yoga. Patients diagnosed with cancer undergoing oncological treatment at two hospitals in Sweden will be included in the study. A preference-based allocation will be used, participants chose self if they want to participate in in-person yoga at a studio or in yoga online. Regardless of allocation, the yoga sessions will take place in a group setting once a week for a duration of 12 weeks. All participants will also have access to a yoga application on their tablets or cell phones, with a recommendation to engage in self-guided yoga for at least 10 minutes per day.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosed with cancer and scheduled for or initiated oncological treatment at an oncology clinic. - Received written information about the study. - Willing to participate in the study and able to follow the protocol. - Understanding and expressing themselves in Swedish. - Age = 18 years. - Provided informed consent. Exclusion Criteria: - Patients with severe cognitive impairments such as dementia and serious psychiatric illness. - Patients with significant physical disabilities that may hinder yoga. - Patients with difficulties completing questionnaires. - Expected survival of less than 3 months.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Medical yoga
Medical yoga is a therapeutic form of Kundalini yoga led by a certified yoga instructor that uses different standardized yoga programs with a combination of physical postures, breathingexercises, and relaxation/meditation.

Locations

Country Name City State
Sweden Department of oncology, university hospital Linköping

Sponsors (3)

Lead Sponsor Collaborator
Linkoeping University Ryhov County Hospital, University Hospital, Linkoeping

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patients preferences to yoga during oncological treatment Interviews on choice of yoga setting: physical or digital Baseline, 3 months and 6 months
Secondary Health-related quality of life Health-related quality of life will be assessed by The European Organisation for Research and Treatment of Cancer, Quality of life Questionnaire C30 (EORTC QLQ-C30) which consists of a 30-item questionnaire, covering a global health status/quality of life (QoL) scale, five functioning scales, three symptom scales and six items concerning symptoms. All scales and single-item measures were transformed to scores in the range 0-100. A higher score on the global status scale and the functional scales denotes a high level of health and functioning, while a higher score on the symptomatic scale denotes a high level of symptom burden Baseline, 3 months and 6 months
Secondary Health Health will be assessed with EuroQoL which consist of two parts: EuroQoL 5 dimensions 5 levels (EQ 5D 5L) and EuroQoL Visual Analogue Scale (EQ-VAS). EQ-5D 5L comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
The EQ-VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can image' =100 and 'The worst health you can image' =0.
Baseline, 3 months and 6 months
Secondary Anxiety and depression The Hospital Anxiety and Depression Scale (HADS) will be used to measure anxiety and depression. The scale consists of 14 items, with seven items related to anxiety and seven related to depression. Each item is scored on a likert scale ranging from 0 to 3, with responses indicating the severity of the symptom from 0=no symptoms to 3= severe symptoms. Baseline, 3 months and 6 months
Secondary Fatigue Fatigue will be assessed with the Multidimensional Fatigue Inventory (MFI). The questionnaire consists of 20 items, measuring five subscales of MFI: General, Physical and Mental Fatigue, Reduced Motivation and Reduced Activity. Each item is scored on a likert scale ranging from 1 to 5. Higher scores indicate higher levels of fatigue. Baseline, 3 months and 6 months
Secondary Sleep Sleep will be measured with Minimal Insomnia Symptom Scale (MISS). The questionnaire consists of 3 items. Each item is scored on a likert scale ranging from 0 to 4, with responses indicating the severity of the symptom from 0=no symptoms to 5= severe symptoms. Baseline, 3 months and 6 months
Secondary Stress Stress will be measured by the questionnaire The Perceived Stress Scale (PSS) which measures general stress and coping capabilities. The instrument has 14 items with 4 alternatives to each item. A higher score indicates higher stress. Each item minimum 0 and maximum 4. Baseline, 3 months and 6 months
Secondary Physical Activity Accelerometer Baseline, 3 months and 6 months
Secondary Adherence to the yoga sessions and the application Attendance at yoga-class and time spent (minutes) using the application At 3 months (After completion of the intervention)
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients